blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3152234

EP3152234 - ANTIBODY WHICH IS DIRECTED AGAINST GALECTIN-9 AND IS AN INHIBITOR OF THE SUPPRESSOR ACTIVITY OF REGULATORY T LYMPHOCYTES [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  24.05.2024
Database last updated on 26.03.2026
FormerThe patent has been granted
Status updated on  05.06.2020
FormerGrant of patent is intended
Status updated on  27.04.2020
FormerExamination is in progress
Status updated on  26.01.2018
FormerRequest for examination was made
Status updated on  10.03.2017
FormerThe international publication has been made
Status updated on  09.12.2016
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
Université de Lille
42, rue Paul Duez
59800 Lille / FR
For all designated states
Centre National de la Recherche Scientifique (C.N.R.S.)
3, rue Michel-Ange
75016 Paris / FR
For all designated states
Institut Gustave Roussy
39, rue Camille Desmoulins
94800 Villejuif / FR
For all designated states
Cellvax
102 avenue Gaston Roussel
93230 Romainville / FR
For all designated states
Université Paris-Saclay
Espace Technologique de Saint-Aubin
Immeuble Discovery
Route de l'Orme des Merisiers - RD 128
91190 Saint-Aubin / FR
[2020/24]
Former [2017/20]For all designated states
Université des Sciences et Technologies de Lille 1
Cité Scientifique
59650 Villeneuve-d'Ascq / FR
For all designated states
Centre National de la Recherche Scientifique (C.N.R.S.)
3, rue Michel-Ange
75016 Paris / FR
For all designated states
Institut Gustave Roussy
39, rue Camille Desmoulins
94800 Villejuif / FR
For all designated states
Cellvax
102 avenue Gaston Roussel
93230 Romainville / FR
For all designated states
Université du Droit et de la Santé de Lille 2
42 rue Paul Duez
59800 Lille / FR
For all designated states
Universite Paris-Sud
15, rue Georges Clémenceau
91400 Orsay / FR
Former [2017/15]For all designated states
Université des Sciences et Technologies de Lille 1
Cité Scientifique
59650 Villeneuve-d'Ascq / FR
For all designated states
Centre National de la Recherche Scientifique (C.N.R.S.)
3, rue Michel-Ange
75016 Paris / FR
For all designated states
Institut Gustave Roussy
39, rue Camille Desmoulins
94800 Villejuif / FR
For all designated states
Cellvax
102 Avenue Gaston Roussel
93230 Romainville / FR
For all designated states
Université du Droit et de la Santé de Lille 2
42 rue Paul Duez
59800 Lille / FR
For all designated states
Universite Paris-Sud
15, rue Georges Clémenceau
91400 Orsay / FR
Inventor(s)01 / DELHEM, Nadira
10 Rue Adolphe Torgue
F-59700 Marcq en Baroeul / FR
02 / BUSSON, Pierre
8 Rue du Moulin
F-92160 Antony / FR
03 / MORALES, Olivier
10/12 Rue du Priez
F-59000 Lille / FR
04 / BARJON, Clément
36 Boulevard Maxime Gorki
F-94800 Villejuif / FR
05 / MRIZAK, Dhafer
101 Rue Colbert
F-59000 Lille / FR
06 / LHUILLIER, Claire
49 Rue du Général Leclerc
F-94270 Le Kremlin-Bicêtre / FR
07 / MUSTAPHA, Rami
275 Rue des Postes (3ème étage)
F-59000 Lille / FR
 [2017/15]
Representative(s)Plasseraud IP
104 Rue de Richelieu
CS92104
75080 Paris Cedex 02 / FR
[N/P]
Former [2020/28]Plasseraud IP
31, rue des Poissonceaux
CS 40009
59044 Lille Cedex / FR
Former [2017/15]Cabinet Plasseraud
31, rue des Poissonceaux
CS 40009
59044 Lille Cedex / FR
Application number, filing date15732846.905.06.2015
[2017/15]
WO2015FR51498
Priority number, dateFR2014005517706.06.2014         Original published format: FR 1455177
[2017/15]
Filing languageFR
Procedural languageFR
PublicationType: A2 Application without search report
No.:WO2015185875
Date:10.12.2015
Language:FR
[2015/49]
Type: A2 Application without search report 
No.:EP3152234
Date:12.04.2017
Language:FR
The application published by WIPO in one of the EPO official languages on 10.12.2015 takes the place of the publication of the European patent application.
[2017/15]
Type: B1 Patent specification 
No.:EP3152234
Date:08.07.2020
Language:FR
[2020/28]
Type: B2 New European patent specification 
No.:EP3152234
Date:26.06.2024
Language:FR
[2024/26]
Search report(s)International search report - published on:EP18.02.2016
ClassificationIPC:A61P35/00, A61P35/02, A61P43/00, C07K16/28, C07K16/30, A61K39/00
[2023/47]
CPC:
C07K16/2851 (EP,US); C07K16/18 (CN,US); A61K39/3955 (US);
A61K45/06 (US); A61P35/00 (EP); A61P35/02 (EP);
A61P43/00 (EP); C07K16/30 (US); C07K16/3084 (EP);
C07K16/3092 (CN,US); A61K2039/505 (EP,US); C07K2317/34 (EP,CN,US);
C07K2317/56 (EP,CN,US); C07K2317/565 (EP,CN,US); C07K2317/76 (EP,CN,US) (-)
Former IPC [2017/15]C07K16/18, C07K16/30
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/15]
TitleGerman:GEGEN GALECTIN-9 GERICHTETER ANTIKÖRPER ALS HEMMER DER SUPPRESSORWIRKUNG VON REGULATORISCHEN T-LYMPHOZYTEN[2017/15]
English:ANTIBODY WHICH IS DIRECTED AGAINST GALECTIN-9 AND IS AN INHIBITOR OF THE SUPPRESSOR ACTIVITY OF REGULATORY T LYMPHOCYTES[2017/15]
French:ANTICORPS DIRIGÉ CONTRE LA GALECTINE 9 ET INHIBITEUR DE L'ACTIVITÉ SUPPRESSIVE DES LYMPHOCYTES T RÉGULATEURS[2017/15]
Entry into regional phase08.12.2016National basic fee paid 
08.12.2016Designation fee(s) paid 
08.12.2016Examination fee paid 
Examination procedure08.12.2016Examination requested  [2017/15]
08.12.2016Date on which the examining division has become responsible
21.07.2017Amendment by applicant (claims and/or description)
29.01.2018Despatch of a communication from the examining division (Time limit: M04)
05.06.2018Reply to a communication from the examining division
07.09.2018Despatch of a communication from the examining division (Time limit: M04)
08.11.2018Reply to a communication from the examining division
07.12.2018Observations by third parties
15.01.2019Observations by third parties
29.03.2019Despatch of a communication from the examining division (Time limit: M08)
09.12.2019Reply to a communication from the examining division
12.02.2020Observations by third parties
17.02.2020Observations by third parties
28.04.2020Communication of intention to grant the patent
30.04.2020Fee for grant paid
30.04.2020Fee for publishing/printing paid
30.04.2020Receipt of the translation of the claim(s)
07.05.2020Observations by third parties
Divisional application(s)EP20184087.3  / EP3747908
Opposition(s)Opponent(s)01  08.04.2021  06.07.2023  WITHDRAWN
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastrasse 30
81925 München / DE
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 [2023/33]
Former [2021/20]
Opponent(s)01  08.04.2021   
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastrasse 30
81925 München / DE
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
23.04.2021Invitation to proprietor to file observations on the notice of opposition
25.10.2021Reply of patent proprietor to notice(s) of opposition
11.07.2023Cancellation of oral proceeding that was planned for 12.09.2023
11.08.2023Despatch of a communication from the opposition division (Time limit: M02)
12.09.2023Date of oral proceedings
11.10.2023Reply to a communication from the opposition division
02.11.2023Despatch of interlocutory decision in opposition
12.11.2023Legal effect of interlocutory decision in opposition
12.02.2024Despatch of communication that the patent will be maintained as amended
Fees paidRenewal fee
30.05.2017Renewal fee patent year 03
28.05.2018Renewal fee patent year 04
27.05.2019Renewal fee patent year 05
22.05.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL08.07.2020
AT08.07.2020
CY08.07.2020
CZ08.07.2020
EE08.07.2020
LV08.07.2020
MC08.07.2020
MK08.07.2020
MT08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SK08.07.2020
SM08.07.2020
TR08.07.2020
BG08.10.2020
[2026/04]
Former [2025/22]AL08.07.2020
AT08.07.2020
CY08.07.2020
CZ08.07.2020
EE08.07.2020
LV08.07.2020
MC08.07.2020
MK08.07.2020
MT08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
Former [2024/52]AL08.07.2020
CY08.07.2020
CZ08.07.2020
EE08.07.2020
LV08.07.2020
MC08.07.2020
MK08.07.2020
MT08.07.2020
NL08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
Former [2024/41]AL08.07.2020
CY08.07.2020
CZ08.07.2020
EE08.07.2020
LV08.07.2020
MC08.07.2020
MK08.07.2020
MT08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
Former [2024/22]AL08.07.2020
CY08.07.2020
CZ08.07.2020
EE08.07.2020
LV08.07.2020
MC08.07.2020
MK08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
Former [2023/30]AL08.07.2020
CY08.07.2020
CZ08.07.2020
EE08.07.2020
LV08.07.2020
MC08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
Former [2022/08]AL08.07.2020
CZ08.07.2020
EE08.07.2020
LV08.07.2020
MC08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
Former [2021/28]AL08.07.2020
CZ08.07.2020
EE08.07.2020
LV08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SK08.07.2020
SM08.07.2020
BG08.10.2020
Former [2021/25]AL08.07.2020
CZ08.07.2020
EE08.07.2020
LV08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SM08.07.2020
BG08.10.2020
Former [2021/22]CZ08.07.2020
EE08.07.2020
LV08.07.2020
PL08.07.2020
RO08.07.2020
RS08.07.2020
SM08.07.2020
BG08.10.2020
Former [2021/10]LV08.07.2020
PL08.07.2020
RS08.07.2020
BG08.10.2020
Cited inInternational search[XI] WO2010084999  (PROTEGENE INC et al.)
 [A] WO2012177788  (JOLLA INST ALLERGY IMMUNOLOG et al.)
 [XI]   CLMENT BARJON ET AL: "A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses", INFECTIOUS AGENTS AND CANCER, BIOMED CENTRAL LTD, LO, vol. 7, no. 1, 17 July 2012 (2012-07-17), pages 16, XP021116920, ISSN: 1750-9378, DOI: 10.1186/1750-9378-7-16

DOI:   http://dx.doi.org/10.1186/1750-9378-7-16
 [I]   KADOWAKI TAKESHI ET AL: "Galectin-9 signaling prolongs survival in murine lung-cancer by inducing macrophages to differentiate into plasmacytoid dendritic cell-like macrophages", CLINICAL IMMUNOLOGY, vol. 142, no. 3, 2012, pages 296 - 307, XP028898525, ISSN: 1521-6616, DOI: 10.1016/J.CLIM.2011.11.006

DOI:   http://dx.doi.org/10.1016/j.clim.2011.11.006
by applicantEP1586325
 WO9514785
 WO9622378
 US5882877
 WO9845322
 EP0173494
   MORALS ET AL.: "Activation of a Helper and Not Regulatory Human CD4+ T Cell Response by Oncolytic H-1 Parvovirus", PLOS ONE, vol. 7, no. 2, 2012, pages E32197
   SEKI ET AL.: "Galectin-9 suppresses the generation of Thl7, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis", CLIN IMMUNOL., vol. 127, no. 1, 20 February 2008 (2008-02-20), pages 78 - 88, XP022535315, DOI: doi:10.1016/j.clim.2008.01.006

DOI:   http://dx.doi.org/10.1016/j.clim.2008.01.006
   GROSSMAN WJ; VERBSKY JW; BARCHET W; COLONNA M; ATKINSON JP; LEY TJ.: "Human T regulatory cells can use the perforin pathway to cause autologous target cell death", IMMUNITY, vol. 21, no. 4, October 2004 (2004-10-01), pages 589 - 601, XP003017082, DOI: doi:10.1016/j.immuni.2004.09.002

DOI:   http://dx.doi.org/10.1016/j.immuni.2004.09.002
   GARIN MI; CHU CC; GOLSHAYAN D; CERNUDA-MOROLLN E; WAIT R; LECHLER RI.: "Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells", BLOOD, vol. 109, no. 5, 1 March 2007 (2007-03-01), pages 2058 - 65, XP002509508, DOI: doi:10.1182/blood-2006-04-016451

DOI:   http://dx.doi.org/10.1182/blood-2006-04-016451
   JOHNSON BD; JING W; ORENTAS RJ.: "CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma", J IMMUNOTHER., vol. 30, no. 2, February 2007 (2007-02-01), pages 203 - 14, XP009125226, DOI: doi:10.1097/01.cji.0000211336.91513.dd

DOI:   http://dx.doi.org/10.1097/01.cji.0000211336.91513.dd
   MCHUGH RS; WHITTERS MJ; PICCIRILLO CA; YOUNG DA; SHEVACH EM; COLLINS M; BYRNE MC.: "CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor", IMMUNITY, vol. 16, no. 2, February 2002 (2002-02-01), pages 311 - 23, XP002247980, DOI: doi:10.1016/S1074-7613(02)00280-7

DOI:   http://dx.doi.org/10.1016/S1074-7613(02)00280-7
   WING K; ONISHI Y; PRIETO-MARTIN P; YAMAGUCHI T; MIYARA M; FEHERVARI Z; NOMURA T; SAKAGUCHI S.: "CTLA-4 control over Foxp3+ regulatory T cell function", SCIENCE, vol. 322, no. 5899, 10 October 2008 (2008-10-10), pages 271 - 5
   ZAHRAN AM ET AL., INT J CLIN ONCOL., 26 September 2013 (2013-09-26)
   FISSON SI; DARRASSE-JZE G; LITVINOVA E; SEPTIER F; KLATZMANN D; LIBLAU R; SALOMON BL.: "Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state", J EXP MED., vol. 198, no. 5, 25 August 2003 (2003-08-25), pages 737 - 46
   XU W ET AL., CANCER RES CLIN ONCOL., vol. 139, no. 11, November 2013 (2013-11-01), pages 1845 - 52
   LADANYI A, MAGY ONKOL., vol. 57, no. 2, June 2013 (2013-06-01), pages 85 - 95
   ZHANG W ET AL., GYNECOL ONCOL., vol. S0090-82, no. 13, 2 January 2014 (2014-01-02), pages 01427 - 3
   FAGHIH Z ET AL., IMMUNOL LETT., vol. 158, no. 1-2, 8 December 2013 (2013-12-08), pages 57 - 65
   AIDA K ET AL., CANCER SCI., 30 November 2013 (2013-11-30)
   HUANG XM ET AL., CANCER SCI., November 2013 (2013-11-01)
   PRESTON CC ET AL., PLOS ONE, vol. 8, no. 11, 14 November 2013 (2013-11-14), pages E80063
   HE M ET AL., NEURO ONCOL., vol. 15, no. 6, June 2013 (2013-06-01), pages 727 - 34
   MUTHU RAJA KR ET AL., PLOS ONE, vol. 7, no. 10, 2012, pages E47077
   DAVIDSON S ET AL., MOD PATHOL., vol. 26, no. 3, March 2013 (2013-03-01), pages 448 - 55
   HUANG Y ET AL., DIGESTION, vol. 86, no. 4, 2012, pages 329 - 37
   MEMARIAN A, TUMOUR BIOL., vol. 34, no. 1, February 2013 (2013-02-01), pages 531 - 42
   DELHEM ET AL., EXPERT OPIN BIOL THER., vol. 10, no. 11, 2010, pages 1563 - 1572
   OUAGUIA ET AL., ISRN HEPATOLOGY, 2013
   CARPENTIER ET AL., AM J TRANSPLANT., vol. 9, no. 9, 2009, pages 2102 - 2112
   MORALS ET AL., BRMI, vol. 2014, 2014
   BAUMFORTH ET AL., AM J PATHOL., vol. 173, no. L, July 2008 (2008-07-01), pages 195 - 204
   MORALS ET AL., PLOSONE, 2014
   KRAUSZ LT ET AL., IDEGGYOGY SZ., vol. 66, no. 9-10, 30 September 2013 (2013-09-30), pages 343 - 8
otherEP15732846
 US8329660
 WO2010084999
 US8329660
 WO2010084999
 US8329660
 WO2010084999
 EP15732846
   KLIBI ET AL.: "Blood diffusion and Th1-suppressive effects of galectin-9containing exosomes released by Epstein-Barr virusinfected nasopharyngeal carcinoma cells", BLOOD, vol. 113, no. 9, 26 February 2009 (2009-02-26), pages 1957 - 1966, XP055538746

DOI:   http://dx.doi.org/10.1182/blood-2008-02-
   BARJON C. ET AL: "A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses", INFECTIOUS AGENTS AND CANCER, vol. 7, no. 1, 17 July 2012 (2012-07-17), pages 16, XP021116920

DOI:   http://dx.doi.org/10.1186/1750-9378-7-16
   LHUILLER C. ET AL: "Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9", PLOS ONE, vol. 13, no. 9, 11 September 2018 (2018-09-11), pages e0202512, XP055538758

DOI:   http://dx.doi.org/10.1371/journal.pone.0202512
   BARJON ET AL.: "A Novel Monoclonal Antibody for the Detection of Galectin-9 in Tissue Sections : Application to Human Tissue Infected by Oncogenic Viruses", INFECTIOUS AGENTS AND CANCER, vol. 7, July 2012 (2012-07-01), XP021116920

DOI:   http://dx.doi.org/10.1186/1750-9378-7-16
   LHUILLIER ET AL.: "Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9", PLOS ONE, vol. 13, no. 9, 11 September 2018 (2018-09-11), pages 1 - 23, XP055538758

DOI:   http://dx.doi.org/10.1371/journal.pone.0202512
   WANG ET AL.: "Tim-3-Galectin-9 Pathway Involves the Suppression Induced by CD4+CD25+ Regulatory T Cells", IMMUNOBIOLOGY, vol. 214, 2009, pages 342 - 349, XP026037212, DOI: 10.1016/j.imbio.2008.10.007

DOI:   http://dx.doi.org/10.1016/j.imbio.2008.10.007
   JU YING; ET AL.,: "The Tim-3/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis", MOLECULAR IMMUNOLOGY, vol. 58, no. 1, 10 December 2013 (2013-12-10), pages 85 - 91, XP028548619

DOI:   http://dx.doi.org/10.1016/j.molimm.2013.11.001
   HASSEN KARED, FABRE THOMAS, BDARD NATHALIE, BRUNEAU JULIE, SHOUKRY NAGLAA H.: "Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C", PLOS PATHOGENS, vol. 9, no. 6, 20 June 2013 (2013-06-20), pages e1003422-1 - e1003422-18, XP055679515

DOI:   http://dx.doi.org/10.1371/journal.ppat.1003422
   WANG ET AL.: "Tim-3-Galectin-9 Pathway Involves the Suppression Induced by CD4+CD25+ Regulatory T Cells", IMMUNOBIOLOGY, vol. 214, 2009, pages 342 - 349, XP026037212, DOI: 10.1016/j.imbio.2008.10.007

DOI:   http://dx.doi.org/10.1016/j.imbio.2008.10.007
   SAKAGUCHI: "Regulatory T Cells: Key Controllers of Immunologic Self-Tolerance", CELL, vol. 101, no. 5, 26 May 2000 (2000-05-26), pages 455 - 458, XP003025450

DOI:   http://dx.doi.org/10.1016/S0092-8674(00)80856-9
   TAAMS ET AL.: "Human anergic/suppressive CD4+ CD25+ T cells: a highly differentiated and apoptosis-prone population", EUR. J. IMMUNOL., vol. 31, no. 4, 29 March 2001 (2001-03-29), pages 1122 - 1131, XP055683382

DOI:   http://dx.doi.org/10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P
   JU ET AL.: "The Tim-3/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis", MOL IMMUNOL, vol. 58, no. 1, 2014, pages 85 - 91, XP028548619, DOI: 10.1016/j.molimm.2013.11.001

DOI:   http://dx.doi.org/10.1016/j.molimm.2013.11.001
   KARED HFABRE TBE'DARD NBRUNEAU JSHOUKRY NH: "Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C", PLOS PATHOG, vol. 9, no. 6, 20 June 2013 (2013-06-20), pages e1003422, XP055679515

DOI:   http://dx.doi.org/10.1371/journal.ppat.1003422
OppositionWO2010084999
 US8329660
 WO2014144600
 WO2016073299
 WO2010084999
 US8329660
 WO2014144600
 WO2016073299
 US201462074779
 WO2021139682
   BARJON ET AL.: "A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses", INFECTIOUS AGENTS AND CANCER, vol. 7, no. 1, 2012, pages 1 - 11, XP021116920, DOI: 10.1186/1750-9378-7-16

DOI:   http://dx.doi.org/10.1186/1750-9378-7-16
   KADOWAKI ET AL.: "Galectin-9 prolongs the survival of septic mice by expanding tim-3-expressing natural killer T cells and PDCA-1+ CDllc+macrophages", CRIT CARE, vol. 17, no. 6, 2013, pages 1 - 11, XP021175303, DOI: 10.1186/cc13147

DOI:   http://dx.doi.org/10.1186/cc13147
   KLIBI ET AL.: "Blood diffusion and Th 1-suppressive effects of galectin-9- containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells", BLOOD, vol. 113, no. 9, 2009, pages 1957 - 66, XP055538746, DOI: 10.1182/blood-2008-02-

DOI:   http://dx.doi.org/10.1182/blood-2008-02-
   LHUILLIER: "Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9", PLOS ONE, vol. 13, no. 9, 2018, pages 1 - 23, XP055538758, DOI: 10.1371/journal.pone.0202512

DOI:   http://dx.doi.org/10.1371/journal.pone.0202512
   CUELLAR LUIS ERNESTO ET AL: "Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience", INFECTIOUS AGENTS AND CANCER, vol. 13, no. 1, 1 December 2018 (2018-12-01), XP055803450, DOI: 10.1186/s13027-018-0200-y

DOI:   http://dx.doi.org/10.1186/s13027-018-0200-y
   SAKAGUCHI: "Regulatory T Cells: Key Controllers of Immunologic Self- Tolerance", CELL, vol. 101, no. 5, 2000, pages 455 - 8, XP003025450, DOI: 10.1016/S0092-8674(00)80856-9

DOI:   http://dx.doi.org/10.1016/S0092-8674(00)80856-9
   TAAMS ET AL.: "Human anergic/suppressive CD 4+ CD 25+ T cells: a highly differentiated and apoptosis-prone population", EUR. J. IMMUNOL., vol. 31, 2001, pages 1122 - 1131, XP055683382, DOI: 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P

DOI:   http://dx.doi.org/10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P
   WANG ET AL.: "Tim-3-Galectin-9 pathway involves the suppression induced by CD 4+ CD 25+ regulatory T cells", IMMUNOBIOLOGY, vol. 214, no. 5, 2009, pages 342 - 9, XP026037212, DOI: 10.1016/j.imbio.2008.10.007

DOI:   http://dx.doi.org/10.1016/j.imbio.2008.10.007
   JU ET AL.: "The Tim-3/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis", MOLECULAR IMMUNOLOGY, vol. 58, no. 1, 2014, pages 85 - 91, XP028548619, DOI: 10.1016/j.molimm.2013.11.001

DOI:   http://dx.doi.org/10.1016/j.molimm.2013.11.001
   HASSEN KARED, FABRE THOMAS, BDARD NATHALIE, BRUNEAU JULIE, SHOUKRY NAGLAA H.: "Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C", PLOS PATHOGENS, vol. 9, no. 6, pages e1003422 - e1003422-18, XP055679515, DOI: 10.1371/journal.ppat.1003422

DOI:   http://dx.doi.org/10.1371/journal.ppat.1003422
   CEDENO-LAURENT ET AL.: "Galectins and their ligands: negative regulators of anti-tumor immunity", GLYCOCONJ J., vol. 29, no. 8-9, 2012, pages 619 - 625, XP035124722, DOI: 10.1007/s10719-012-9379-0

DOI:   http://dx.doi.org/10.1007/s10719-012-9379-0
   MOUGLAKAKOS DIMITRIOS, ET AL: "Regulatory T Cells in Cancer", ADVANCES IN CANCER RESEARCH, vol. 107, 1 January 2010 (2010-01-01), pages 57 - 117, XP055803461
   RABINOVICH ET AL.: "Regulatory Circuits Mediated by Lectin-Glycan Interactions in Autoimmunity and Cancer", IMMUNITY, vol. 36, no. 3, 2012, pages 322 - 35, XP028475161, DOI: 10.1016/j.immuni.2012.03.004

DOI:   http://dx.doi.org/10.1016/j.immuni.2012.03.004
   HEUSSCHEN ROY, ET AL: "Galectin-9 in tumor biology: A jack of multiple trades", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - REVIEWS ON CANCER, vol. 1836, 1 January 2013 (2013-01-01), pages 177 - 185, XP055803466
   TPFER KATRIN ET AL: "Tumor Evasion from T Cell Surveillance", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, vol. 2011, 1 January 2011 (2011-01-01), pages 1 - 19, XP055803537, ISSN: 1110-7243, DOI: 10.1155/2011/918471

DOI:   http://dx.doi.org/10.1155/2011/918471
   SAKAGUCHI: "Naturally arising Foxp3-expressing CD 25+ CD 4+ regulatory T cells in immunological tolerance to self and non-self", NATURE IMMUNOLOGY, vol. 6, no. 4, 2005, pages 345 - 52, XP002394639, DOI: 10.1038/ni1178

DOI:   http://dx.doi.org/10.1038/ni1178
   AERTS JOACHIM G., HEGMANS JOOST P.: "Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 73, no. 8, 15 April 2013 (2013-04-15), US, pages 2381 - 2388, XP055803539, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-3932

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-12-3932
   FUJIHARA ET AL.: "Galectin-9 in Cancer Therapy", RECENT PAT ENDOCR METAB IMMUNE DRUG DISCOV., vol. 7, no. 2, 2013, pages 130 - 7, XP055494562, DOI: 10.2174/1872214811307020006

DOI:   http://dx.doi.org/10.2174/1872214811307020006
   MCMURCHY ET AL.: "Suppression assays with human T regulatory cells: A technical guide", EUR. J. IMMUNOL., vol. 42, no. 1, 2012, pages 27 - 34, XP055142943, DOI: 10.1002/eji.201141651

DOI:   http://dx.doi.org/10.1002/eji.201141651
   AVALOS-MARTINEZ CLAUDIA E: "Measurement of suppressor activity of T CD 4+ CD 25+ T reg cells using bromodeoxyuridine incorporation assay", IMMUNOL INVEST., vol. 42, no. 4, 1 January 2013 (2013-01-01), pages 369 - 381, XP055803547
   ANDREA LADNYI: "A tumort infiltrl immunsejtek prognosztikai rtke melanmban", MAGYAR ONKOLGIA, 1 January 2013 (2013-01-01), pages 85 - 95, XP055803613, Retrieved from the Internet [retrieved on 20210511] * . Hungarian. *
   GOODEN M J M, DE BOCK G H, LEFFERS N, DAEMEN T, NIJMAN H W: "The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 105, no. 1, 1 June 2011 (2011-06-01), GB, pages 93 - 103, XP055803621, ISSN: 0007-0920, DOI: 10.1038/bjc.2011.189

DOI:   http://dx.doi.org/10.1038/bjc.2011.189
   BARJON: "Caractrisation biochimique et fonctionnelle de nouveaux anticorps monoclonaux anti-galectine-9 en vue d'applications diagnostiques et thrapeutiques", THSE DE DOCTORAT EN CANCROLOGIE, IMMUNOLOGIE, BIOLOGIE CELLULAIRE, BIOCHIMIE, 5 February 2013 (2013-02-05), pages 1 - 128
   RABINOVICH G. A., LIU F.-T., HIRASHIMA M., ANDERSON A.: "An Emerging Role for Galectins in Tuning the Immune Response: Lessons from Experimental Models of Inflammatory Disease, Autoimmunity and Cancer", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, vol. 66, no. 2-3, 1 August 2007 (2007-08-01), GB, pages 143 - 158, XP055803633, ISSN: 0300-9475, DOI: 10.1111/j.1365-3083.2007.01986.x

DOI:   http://dx.doi.org/10.1111/j.1365-3083.2007.01986.x
   LIBERAL RODRIGO ET AL: "The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway", HEPATOLOGY, JOHN WILEY & SONS, INC., US, vol. 56, no. 2, 1 August 2012 (2012-08-01), US, pages 677 - 686, XP055803638, ISSN: 0270-9139, DOI: 10.1002/hep.25682

DOI:   http://dx.doi.org/10.1002/hep.25682
   IRIE ET AL.: "Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer", CLIN CANCER RES., vol. 11, no. 8, 2005, pages 2962 - 8, XP002432614, DOI: 10.1158/1078-0432.CCR-04-0861

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-04-0861
   NOBUMOTO A., ET AL: "Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices", GLYCOBIOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 18, no. 9, 1 January 2008 (2008-01-01), US, pages 735 - 744, XP055803643, ISSN: 0959-6658, DOI: 10.1093/glycob/cwn062

DOI:   http://dx.doi.org/10.1093/glycob/cwn062
   KOBAYASHI T, ET AL: "Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways", LEUKEMIA, STOCKTON PRESS, LONDON, vol. 24, no. 4, 1 April 2010 (2010-04-01), London, pages 843 - 850, XP055803648, ISSN: 0887-6924, DOI: 10.1038/leu.2010.25

DOI:   http://dx.doi.org/10.1038/leu.2010.25
   JIANG JING, ET AL: "Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer", PLOS ONE, vol. 8, no. 12, 1 December 2013 (2013-12-01), pages e81799, XP055803651, DOI: 10.1371/journal.pone.0081799

DOI:   http://dx.doi.org/10.1371/journal.pone.0081799
   YANG JIAXING, ZHU LIN, CAI YONG, SUO JIAN, JIN JINGJI: "Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer", INTERNATIONAL JOURNAL OF ONCOLOGY, DEMETRIOS A. SPANDIDOS ED. & PUB, GR, vol. 45, no. 3, 1 September 2014 (2014-09-01), GR, pages 1313 - 1320, XP055803657, ISSN: 1019-6439, DOI: 10.3892/ijo.2014.2494

DOI:   http://dx.doi.org/10.3892/ijo.2014.2494
   FUJITA KOJI, ET AL: "Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo", INTERNATIONAL JOURNAL OF ONCOLOGY, DEMETRIOS A. SPANDIDOS ED. & PUB, GR, vol. 46, no. 6, 1 June 2015 (2015-06-01), GR, pages 2419 - 2430, XP055803662, ISSN: 1019-6439, DOI: 10.3892/ijo.2015.2941

DOI:   http://dx.doi.org/10.3892/ijo.2015.2941
   WANG KAI, CHEN ZHEN, WU RONGZU, YIN JUN, FAN MIN, XU XIANLIN: "Prognostic Role of High Gal-9 Expression in Solid Tumours: a Meta-Analysis", CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, KARGER BASEL, CH, vol. 45, no. 3, 1 January 2018 (2018-01-01), CH, pages 993 - 1002, XP055803667, ISSN: 1015-8987, DOI: 10.1159/000487294

DOI:   http://dx.doi.org/10.1159/000487294
   SUN QIQING, ET AL: "Prognostic and diagnostic signifcance of galectins in pancreatic cancer: a systematic review and meta-analysis", CANCER CELL INTERNATIONAL, vol. 19, no. 309, 1 December 2019 (2019-12-01), pages 1 - 14, XP055803669, DOI: 10.1186/s12935-019-1025-5

DOI:   http://dx.doi.org/10.1186/s12935-019-1025-5
   AKIMOVA TATIANA, HANCOCK WAYNE W.: "How little is known about the role of human FOXP3+ Tregs in tumors", EXPERT OPINION ON THERAPEUTIC TARGETS, INFORMA HEALTHCARE, UK, vol. 22, no. 8, 3 August 2018 (2018-08-03), UK , pages 655 - 658, XP093119760, ISSN: 1472-8222, DOI: 10.1080/14728222.2018.1499728

DOI:   http://dx.doi.org/10.1080/14728222.2018.1499728
   BARJON ET AL.: "A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses", INFECTIOUS AGENTS AND CANCER, vol. 7, no. 1, 2012, pages 1 - 11, DOI: 10.1186/1750-9378-7-16
   KADOWAKI ET AL.: "Galectin-9 prolongs the survival of septic mice by expanding tim-3-expressing natural killer T cells and PDCA-1+ CDllc+macrophages", CRIT CARE, vol. 17, no. 6, 2013, pages 1 - 11, DOI: 10.1186/cc13147
   KLIBI ET AL.: "Blood diffusion and Th 1-suppressive effects of galectin-9- containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells", BLOOD, vol. 113, no. 9, 2009, pages 1957 - 66, DOI: 10.1182/blood-2008-02-
   LHUILLIER: "Characterization of neutralizing antibodies reacting with the 213-224 amino-acid segment of human galectin-9", PLOS ONE, vol. 13, no. 9, 2018, pages 1 - 23, DOI: 10.1371/journal.pone.0202512
   Comparative tests filed by the Patentees Prior to grant
   CUELLAR LUIS ERNESTO ET AL: "Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience", INFECTIOUS AGENTS AND CANCER, vol. 13, no. 1, 1 December 2018 (2018-12-01), DOI: 10.1186/s13027-018-0200-y
   SAKAGUCHI: "Regulatory T Cells: Key Controllers of Immunologic Self- Tolerance", CELL, vol. 101, no. 5, 2000, pages 455 - 8, DOI: 10.1016/S0092-8674(00)80856-9
   TAAMS ET AL.: "Human anergic/suppressive CD 4+ CD 25+ T cells: a highly differentiated and apoptosis-prone population", EUR. J. IMMUNOL., vol. 31, 2001, pages 1122 - 1131, DOI: 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P
   WANG ET AL.: "Tim-3-Galectin-9 pathway involves the suppression induced by CD 4+ CD 25+ regulatory T cells", IMMUNOBIOLOGY, vol. 214, no. 5, 2009, pages 342 - 9, DOI: 10.1016/j.imbio.2008.10.007
   JU ET AL.: "The Tim-3/galectin-9 pathway involves in the homeostasis of hepatic Tregs in a mouse model of concanavalin A-induced hepatitis", MOLECULAR IMMUNOLOGY, vol. 58, no. 1, 2014, pages 85 - 91, DOI: 10.1016/j.molimm.2013.11.001
   HASSEN KARED, FABRE THOMAS, BDARD NATHALIE, BRUNEAU JULIE, SHOUKRY NAGLAA H.: "Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C", PLOS PATHOGENS, vol. 9, no. 6, pages e1003422 - e1003422-18, DOI: 10.1371/journal.ppat.1003422
   CEDENO-LAURENT ET AL.: "Galectins and their ligands: negative regulators of anti-tumor immunity", GLYCOCONJ J., vol. 29, no. 8-9, 2012, pages 619 - 625, DOI: 10.1007/s10719-012-9379-0
   MOUGLAKAKOS DIMITRIOS, ET AL: "Regulatory T Cells in Cancer", ADVANCES IN CANCER RESEARCH, vol. 107, 1 January 2010 (2010-01-01), pages 57 - 117
   RABINOVICH ET AL.: "Regulatory Circuits Mediated by Lectin-Glycan Interactions in Autoimmunity and Cancer", IMMUNITY, vol. 36, no. 3, 2012, pages 322 - 35, DOI: 10.1016/j.immuni.2012.03.004
   HEUSSCHEN ROY, ET AL: "Galectin-9 in tumor biology: A jack of multiple trades", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - REVIEWS ON CANCER, vol. 1836, 1 January 2013 (2013-01-01), pages 177 - 185
   TPFER KATRIN ET AL: "Tumor Evasion from T Cell Surveillance", JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, vol. 2011, 1 January 2011 (2011-01-01), pages 1 - 19, ISSN: 1110-7243, DOI: 10.1155/2011/918471
   SAKAGUCHI: "Naturally arising Foxp3-expressing CD 25+ CD 4+ regulatory T cells in immunological tolerance to self and non-self", NATURE IMMUNOLOGY, vol. 6, no. 4, 2005, pages 345 - 52, DOI: 10.1038/ni1178
   AERTS JOACHIM G., HEGMANS JOOST P.: "Tumor-Specific Cytotoxic T Cells Are Crucial for Efficacy of Immunomodulatory Antibodies in Patients with Lung Cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 73, no. 8, 15 April 2013 (2013-04-15), US, pages 2381 - 2388, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-3932
   FUJIHARA ET AL.: "Galectin-9 in Cancer Therapy", RECENT PAT ENDOCR METAB IMMUNE DRUG DISCOV., vol. 7, no. 2, 2013, pages 130 - 7, DOI: 10.2174/1872214811307020006
   MCMURCHY ET AL.: "Suppression assays with human T regulatory cells: A technical guide", EUR. J. IMMUNOL., vol. 42, no. 1, 2012, pages 27 - 34, DOI: 10.1002/eji.201141651
   AVALOS-MARTINEZ CLAUDIA E: "Measurement of suppressor activity of T CD 4+ CD 25+ T reg cells using bromodeoxyuridine incorporation assay", IMMUNOL INVEST., vol. 42, no. 4, 1 January 2013 (2013-01-01), pages 369 - 381
   Binding experiments with anti- Gal- 9 antibodies
   Proliferation experiments with anti- Gal -9 antibodies * . Hungarian. *
   NPC xenograft experiments with antibodies 1G3 and 2E12 in mouse
   ANDREA LADNYI: "A tumort infiltrl immunsejtek prognosztikai rtke melanmban", MAGYAR ONKOLGIA, 1 January 2013 (2013-01-01), pages 85 - 95, Retrieved from the Internet [retrieved on 20210511]
   English translation of D27 (machine translation by google translate)
   GOODEN M J M, DE BOCK G H, LEFFERS N, DAEMEN T, NIJMAN H W: "The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 105, no. 1, 1 June 2011 (2011-06-01), GB, pages 93 - 103, ISSN: 0007-0920, DOI: 10.1038/bjc.2011.189
   BARJON: "Caractrisation biochimique et fonctionnelle de nouveaux anticorps monoclonaux anti-galectine-9 en vue d'applications diagnostiques et thrapeutiques", THSE DE DOCTORAT EN CANCROLOGIE, IMMUNOLOGIE, BIOLOGIE CELLULAIRE, BIOCHIMIE, 5 February 2013 (2013-02-05), pages 1 - 128
   IDS tiled by Patentee in the US admitting that the Barjon Doctoral Thesis was published in 2013
   Database references confirming that the Barjon Doctoral Thesis was published in 2013
   RABINOVICH G. A., LIU F.-T., HIRASHIMA M., ANDERSON A.: "An Emerging Role for Galectins in Tuning the Immune Response: Lessons from Experimental Models of Inflammatory Disease, Autoimmunity and Cancer", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, vol. 66, no. 2-3, 1 August 2007 (2007-08-01), GB, pages 143 - 158, ISSN: 0300-9475, DOI: 10.1111/j.1365-3083.2007.01986.x
   LIBERAL RODRIGO ET AL: "The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9/tim-3 pathway", HEPATOLOGY, JOHN WILEY & SONS, INC., US, vol. 56, no. 2, 1 August 2012 (2012-08-01), US, pages 677 - 686, ISSN: 0270-9139, DOI: 10.1002/hep.25682
   Evidence that 1G3 was commercially available at least by May 2015
   IRIE ET AL.: "Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer", CLIN CANCER RES., vol. 11, no. 8, 2005, pages 2962 - 8, DOI: 10.1158/1078-0432.CCR-04-0861
   NOBUMOTO A., ET AL: "Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices", GLYCOBIOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 18, no. 9, 1 January 2008 (2008-01-01), US, pages 735 - 744, ISSN: 0959-6658, DOI: 10.1093/glycob/cwn062
   KOBAYASHI T, ET AL: "Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways", LEUKEMIA, STOCKTON PRESS, LONDON, vol. 24, no. 4, 1 April 2010 (2010-04-01), London, pages 843 - 850, ISSN: 0887-6924, DOI: 10.1038/leu.2010.25
   JIANG JING, ET AL: "Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer", PLOS ONE, vol. 8, no. 12, 1 December 2013 (2013-12-01), pages e81799, DOI: 10.1371/journal.pone.0081799
   YANG JIAXING, ZHU LIN, CAI YONG, SUO JIAN, JIN JINGJI: "Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer", INTERNATIONAL JOURNAL OF ONCOLOGY, DEMETRIOS A. SPANDIDOS ED. & PUB, GR, vol. 45, no. 3, 1 September 2014 (2014-09-01), GR, pages 1313 - 1320, ISSN: 1019-6439, DOI: 10.3892/ijo.2014.2494
   FUJITA KOJI, ET AL: "Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo", INTERNATIONAL JOURNAL OF ONCOLOGY, DEMETRIOS A. SPANDIDOS ED. & PUB, GR, vol. 46, no. 6, 1 June 2015 (2015-06-01), GR, pages 2419 - 2430, ISSN: 1019-6439, DOI: 10.3892/ijo.2015.2941
   WANG KAI, CHEN ZHEN, WU RONGZU, YIN JUN, FAN MIN, XU XIANLIN: "Prognostic Role of High Gal-9 Expression in Solid Tumours: a Meta-Analysis", CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, KARGER BASEL, CH, vol. 45, no. 3, 1 January 2018 (2018-01-01), CH, pages 993 - 1002, ISSN: 1015-8987, DOI: 10.1159/000487294
   SUN QIQING, ET AL: "Prognostic and diagnostic signifcance of galectins in pancreatic cancer: a systematic review and meta-analysis", CANCER CELL INTERNATIONAL, vol. 19, no. 309, 1 December 2019 (2019-12-01), pages 1 - 14, DOI: 10.1186/s12935-019-1025-5
   Translation D27
   Poster by Margall II
   AKIMOVA TATIANA, HANCOCK WAYNE W.: "How little is known about the role of human FOXP3+ Tregs in tumors", EXPERT OPINION ON THERAPEUTIC TARGETS, INFORMA HEALTHCARE, UK, vol. 22, no. 8, 3 August 2018 (2018-08-03), UK , pages 655 - 658, ISSN: 1472-8222, DOI: 10.1080/14728222.2018.1499728
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.